Izumi Ohno

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen et al. · The Lancet Oncology · 2019 · 1.6K citations

Oncology, Hepatology, α-Fetoprotein Concentrations +10

Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

Makoto Ueno, Masafumi Ikeda, Chigusa Morizane et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 328 citations

Urology, Cisplatin Plus Gemcitabine, Gastrointestinal Oncology +8

Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer

Shuichi Mitsunaga, Masafumi Ikeda, Satoshi Shimizu et al. · British Journal of Cancer · 2013 · 152 citations · Full text

NADPH Oxidase Promotes Pancreatic Cancer Cell Survival via Inhibiting JAK2 Dephosphorylation by Tyrosine Phosphatases

Jong Kyun Lee, Mouad Edderkaoui, Patrick Alan Truong et al. · Gastroenterology · 2007 · 150 citations · Full text

Signal Transduction, Pancreatic Cancer, Biochemistry +14

Ellagic acid induces apoptosis through inhibition of nuclear factor kB in pancreatic cancer cells

Mouad Edderkaoui, Irina Odinokova, Izumi Ohno et al. · World Journal of Gastroenterology · 2008 · 137 citations · Full text